|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Ellis, MJ, Gillette, M, Carr, SA, Paulovich, AG, Smith, RD, Rodland, KK, Townsend, RR, Kinsinger, C, Mesri, M, Rodriguez, H, Liebler, DC, Clinical Proteomic Tumor Analysis Consortium, (CPTAC)|
Summary: The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods. Cancer Discov; 3(10); 1108-12. ©2013 AACR.